ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Halozyme Therapeutics Incorporated

Halozyme Therapeutics Incorporated (HALO)

40.68
-0.05
(-0.12%)
Closed March 29 04:00PM
40.86
0.18
(0.44%)
After Hours: 07:57PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
40.86
Bid
39.75
Ask
41.30
Volume
707,395
40.44 Day's Range 40.99
29.85 52 Week Range 45.00
Market Cap
Previous Close
40.73
Open
40.82
Last Trade Time
Financial Volume
$ 28,825,944
VWAP
40.7494
Average Volume (3m)
1,349,823
Shares Outstanding
126,824,800
Dividend Yield
-
PE Ratio
18.31
Earnings Per Share (EPS)
2.22
Revenue
829.25M
Net Profit
281.59M

About Halozyme Therapeutics Incorporated

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeut... Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
1970
Halozyme Therapeutics Incorporated is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker HALO. The last closing price for Halozyme Therapeutics was $40.73. Over the last year, Halozyme Therapeutics shares have traded in a share price range of $ 29.85 to $ 45.00.

Halozyme Therapeutics currently has 126,824,800 shares outstanding. The market capitalization of Halozyme Therapeutics is $5.16 billion. Halozyme Therapeutics has a price to earnings ratio (PE ratio) of 18.31.

HALO Latest News

Form PRE 14A - Other preliminary proxy statements

0001159036PRE 14Afalse00011590362023-01-012023-12-31iso4217:USD00011590362022-01-012022-12-3100011590362021-01-012021-12-3100011590362020-01-012020-12-310001159036ecd:PeoMemberhalo:EquityAwardsOpti...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 144 - Report of proposed sale of securities

="/Images/box-unchecked.jpg" alt="Checkbox not checked">252902/16/2024Not Applicable* If the securities were purchased and full payment therefor was not made in cash at the time of purchase...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 144 - Report of proposed sale of securities

="/Images/box-unchecked.jpg" alt="Checkbox not checked">217802/15/2024Not Applicable* If the securities were purchased and full payment therefor was not made in cash at the time of purchase...

Halozyme to Participate in Upcoming Investor Conferences

Halozyme to Participate in Upcoming Investor Conferences PR Newswire SAN DIEGO, Feb. 27, 2024 SAN DIEGO, Feb. 27, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.170.4177930695540.6942.339.972464240.28686827CS
40.621.540755467240.2442.6439.3998306840.90079342CS
124.9813.879598662235.8842.6433.15134982337.01915496CS
262.456.3785472533238.4142.8232.83114312737.32783366CS
525.3214.969048958935.544529.85113148237.27786877CS
156-0.14-0.3414634146344159.4629.85110531541.25035965CS
26025.24161.58770806715.6259.4612.71119628034.53883413CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

HALO Discussion

View Posts
Fred Kadiddlehopper Fred Kadiddlehopper 2 hours ago
There is no indication when patents will be granted, but I don't think it will move the needle outside of the current rangebound limits at all. By the way, we've reached the end of the quarter with yet another goose egg for new deals. I'm starting to think that we are being actively lied to when HALO trumpets all the interest in partnerships that are supposedly percolating.
👍️0
Howeeme Howeeme 17 hours ago
Probably not. You can’t blame someone for cashing in stock. It’s not like he’s selling into major strength. He’s not timing this just selling to pick up some cash. Maybe he wants a vacation home. I never look at program insider selling as a major negative. There hasn’t been any insider buying in a long time which concerns me a little bit but the buybacks can be looked at as an indirect way of insider buying I guess.
On another note I think that it takes at least a couple years to integrate an acquisition so we’ll see if it was money well spent soon enough. Certainly looks like it’s been accretive so far not that much.
I’m not a big fan of companies that over hype their stock with BS announcements so lack of announcements doesn’t bother me as much as it does others in this thread. There seems to be a lot of positive stuff going on just not a lot of PR. That being said if you call the company they should call back. No response is not acceptable.
👍️ 1
biotechinvestor1 biotechinvestor1 17 hours ago
Fantastic tweet from today:

“I ran a screener of

ROIC 3yr Average >20%
FCF margin 3yr Average >15%
Revenue Growth >25%

The top 4 Results were
1) Nvidia $NVDA
(46% / 28% / 125%)
2) Booking Holdings $BKNG
(28% / 28% / 25%)
3)Arista Networks $ANET
(51% / 25% / 33%)
4)Halozyme $HALO
(42% / 47% / 25%)”
👍️0
maumar maumar 20 hours ago
I took a closer look at the slides. There is a patent pending for Tecentriq SC, Ocrevus SC and Hytrulo. Have they said when they expect these patents to be granted? If they do get granted, it'll make a significant difference.
👍️0
easycomeandgo easycomeandgo 22 hours ago
It is not for me to reply to your question, it wasn’t addressed to me. Besides, I have no idea of what LaBarre is doing with his 10b-5. I can categorically say that a discussion is not easy. Reading the board, one comes away with the impression that for some unknown reason Halozyme management is intent on subverting the company’s stock, doing all they can, in defiance of its amazing promise, to knock any and all support from under it. They do not respond to belligerent interrogatives, corporate communications has taken upon itself to destroy the place of its employment, as they successfully did with the stellar company Antares. We probably need a resident shrink on the message board to attempt to deal with the persecution complex that rules. After reading the posts, one has to ask oneself, why on earth would I invest money in this thing? Good question, in any case… If management is so evil, why own the stock? Why, indeed…
👍️0
Fred Kadiddlehopper Fred Kadiddlehopper 22 hours ago
Howee do you believe LaBarre has cancelled his 10b-5 selling plan?
👍️0
biotechinvestor1 biotechinvestor1 1 day ago
I could not agree more.

Apparently, halozyme has hired a new PR firm to help them. But we have an IR problem as well. She does not respond to any form of communication.

👍️0
stockrafter stockrafter 1 day ago
Disappointing to say the least, and it makes one wonder why….

Viatris had a good presentation on Selatogrel yesterday. Pointing out the block buster potential of the drug-auto injector combo, but SADLY no mention of Halozyme supplying the auto injector. Then again, an investor would never know Halozyme is suppling the fully packaged Selatogrel-AI combo to Viatris, from any info Halozyme posts.

Idorsia would always have some good words for the Antares autoinjector in their presentations, and Antares had it in their presentations.

Why is that?

Even if the product is years away, why not let it be known another firm is interested in Halozyme auto-injector?

Is there a PR problem here or what? Should be paying me for investor updating PR services……….

If not for the little pictures in the presentations, one would never know the Halozyme connection. Sad.

https://investor.viatris.com/static-files/b01a07f3-e549-4522-8480-c31b359a6a4f

An EpiPen For Heart Attacks? Idorsia Launches Phase III Study Of Selatogrel

Pic of AI

https://scrip.citeline.com/SC144926/An-EpiPen-For-Heart-Attacks-Idorsia-Launches-Phase-III-Study-Of-Selatogrel

Pic of AI on ATRS presentation….

“SUPPLY fully packaged product at cost plus margin and ROYALTIES escalating to low double digits”

https://static.seekingalpha.com/uploads/sa_presentations/696/80696/original.pdf
👍️ 1
Howeeme Howeeme 2 days ago
Labarre should have plenty of money to pay tax on a few shares from the 20k per month he’s been selling. I think it’s a non event but fun to talk about anyway.
👍️0
Fred Kadiddlehopper Fred Kadiddlehopper 2 days ago
What a slender thread on which to hang one's hopes.
👍️0
biotechinvestor1 biotechinvestor1 3 days ago
am I dreaming? Are my eyes deceiving me? Did LaBarre just convert some options and held onto the shares without selling a single one? This is welcomed news. https://d18rn0p25nwr6d.cloudfront.net/CIK-0001159036/465f2965-ed25-4e96-9042-6b62a53e45e3.pdf
👍️0
Howeeme Howeeme 1 week ago
Saw this in the morning when stock was up close to 2 bucks. Was kind of surprised it fizzled out. Oh well.
👍️0
Fred Kadiddlehopper Fred Kadiddlehopper 1 week ago
ARGX up as Roche/Chugai autoimmune disease drug disappoints in closely watched trial

BioPharma Dive· Industry Dive
Jonathan Gardner
Thu, Mar 21, 2024, 8:08 AM EDT2 min read

In This Article:
ROG.SW
-2.55%
AZN.L
+2.60%
An autoimmune disease drug from Roche and Chugai Pharmaceutical hit its main goal in a closely watched trial, but the results of the study, in a condition called myasthenia gravis, “did not reach our expectations,” the companies said Thursday.

Roche and Chugai have already brought the drug, known as Enspryng, to market for the rare eye condition neuromyelitis optica spectrum disorder. But the companies are working to expand its use elsewhere, including in myasthenia gravis, an autoimmune condition characterized by muscle weakness.

In recent years, myasthenia gravis has become a competitive area among drugmakers. AstraZeneca’s Soliris and Ultomiris are among the medicines available. More recently, Argenx’s Vyvgart became the first of a newer group of so-called FcRn inhibitors to get to market and has gotten off to a strong launch. Johnson & Johnson and Immunovant are advancing FcRn blockers as well.

Those drugs, though, faced a potential competitive threat from Enspryng. Recently published study results showed that tocilizumab, a drug that works similarly to Enspryng, might be an effective treatment for myasthenia gravis. That, in turn, had stoked fear among investors that the Enspyring trial could establish medicines like it, IL-6 inhibitors, as a “new standard-of-care” with “differentiated efficacy” and less frequent dosing than FcRn drugs, wrote Leerink Partners analyst Thomas Smith, in a note to clients Thursday.

The study tested Enspyrng in a trial that randomized 185 patients to receive the drug or a placebo over 24 weeks. The main goal was to outperform a placebo on a 24-point questionnaire.

Chugai revealed Thursday that Enspyring fell short of expectations on the “degree of clinical benefit” in the trial. The company didn’t provide further details, saving them instead for a medical meeting next month. It’ll continue developing Enspryng for other rare inflammatory conditions, such as thyroid eye disease and autoimmune encephalitis.

In the meantime, the effects of the findings rippled across to other developers. Argenx shared climbed 12% in Thursday morning trading, while Immunovant’s stock initially surged double digits before settling in to a smaller gain. Shares of Tourmaline Bio, which is developing an IL-6 drug for myasthenia gravis, fell nearly 40%.

Smith, of Leerink, expects the results “to be viewed as confirmation of FcRn’s current role as the preferred [target]” for the disease.

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter.

https://finance.yahoo.com/news/roche-autoimmune-disease-drug-disappoints-120800457.html?.tsrc=fin-srch
👍️0
biotechinvestor1 biotechinvestor1 1 week ago
what’s going on with Halozyme’s IR? emails unanswered, voice messages unreturned, requests to speak with executives ignored, multiple new trials, and no PR. The investors deserve better.
👍️ 2
stockrafter stockrafter 2 weeks ago
They certainly make it confusing doing DD on their drugs, by continuously changing the names all the time.

It seems to be "N6LS BNAB" on the bottom of the pipeline, that is for some reason hidden, could not find the link from HALO home page.

The imagine in the partner column is from "Vaccine Research Center, National Institutes of Health."

https://halozyme.com/pipeline-build/

https://en.wikipedia.org/wiki/File:VRC-NIH_logo.png
👍️0
biotechinvestor1 biotechinvestor1 2 weeks ago
Pace of new trials with Enhanze seems to be picking back up. 3 new ones just in the past week. Things were quiet for a while.
👍️ 3
biotechinvestor1 biotechinvestor1 2 weeks ago
Another brand new study with Enhanze (first posted on 3/15/24).

Phase 1 GSK/Viiv trial + Enhanze on a brand new antiviral:

https://classic.clinicaltrials.gov/ct2/show/NCT06310551?term=Rhuph20&draw=4&rank=122
👍️ 2
biotechinvestor1 biotechinvestor1 2 weeks ago
According to Table 2, the 10ml HVAI’s are in “development.”

Helen said that Halo’s 10ml HVAI is the first ever and no one else has done successfully in humans.

It seems that halo is ahead of
👍️ 1
Fred Kadiddlehopper Fred Kadiddlehopper 2 weeks ago
Thanks for the clarification!!
👍️0
stockrafter stockrafter 2 weeks ago
Halo is not the only firm with large volume AI, and they certainly were late to the game. Halo does seem to have the largest volume deliverable of 25 ml. No reason the other firms can not develop a HVAI, since some already have 10 ml injectors. But the other firms do not have Enhanze to pair with the HVAI.

"Table 2. An overview of investigational large-volume handheld autoinjectors with pre-filled syringes and cartridges exceeding 2.25 mL capacity."

https://www.tandfonline.com/doi/pdf/10.1080/17425247.2023.2219891
👍️0
stockrafter stockrafter 2 weeks ago
A little confusing, but in any case they are not giving up on SC injection, for reasons pointed out in the article, and the info in the patent, because SC allows for self-injection.

".............and additional evaluation of subcutaneous administration is planned. Unlike intramuscular injections, subcutaneous shots could potentially allow for self-administration.”

Skim through the patent posted earlier......They are looking at the two stage reconstitution injector.

35. A multi-compartment container, comprising a suspension comprising cabotegravir in one compartment, and a soluble hyaluronidase in a second compartment.

36. The multi-compartment container of claim 35 that is a syringe, comprising two compartments.
👍️ 1
biotechinvestor1 biotechinvestor1 2 weeks ago
Much is happening in the AI (autoinjector) world and halozyme is far ahead of everyone else with it’s exquisite HVAI. Once we have a HVAI deal, there will be a buzz that will take share price to all time new highs.
👍️ 2
Fred Kadiddlehopper Fred Kadiddlehopper 2 weeks ago
Sorry to sound obstreperous, but there is nothing in that article that indicates Enhanz will be involved in the development of CAB-ULA in either iteration, whether subcu or IM.

Thanks for the Idorsia info. That was a deep dive!
👍️0
stockrafter stockrafter 2 weeks ago
Yes, ending with CAB200, but will continue on with SC CAB-ULA……….”Intramuscular CAB-ULA given every four months will now progress to late-stage PrEP and treatment trials, and additional evaluation of subcutaneous administration is planned. Unlike intramuscular injections, subcutaneous shots could potentially allow for self-administration.” Therefore the autoinjector......

And to earlier post....

Idorsia has a deal with ATRS to use their auto injector with Selatogrel, unless it was dropped with the Viatris deal, which would be unlikely with all the development and trials conducted using the ATRS AI.

https://www.idorsia.com/investors/news-and-events/media-releases/media-release-details?id=2206504

Well the last of my 3 posts today…..
👍️ 1
Fred Kadiddlehopper Fred Kadiddlehopper 2 weeks ago
FRom the article you posted recently
Based on these findings, the researchers concluded that CAB200 with rHuPH20 has “low potential” for less frequent dosing, and it will not move forward. But the new ultra-long-acting formulation has a favorable tolerability and safety profile with a pharmacokinetic profile that supports dose intervals of four months or more.
https://www.poz.com/article/ultralongacting-cabotegravir-given-every-four-months
👍️0
Fred Kadiddlehopper Fred Kadiddlehopper 2 weeks ago
While AI's are mentioned in the articles, I didn't see any confirmation that they were ATRS products. Did I miss something?
👍️0
stockrafter stockrafter 2 weeks ago
Thanks, interestingly did not see selatogrel in the presentation nor mention of Idorsia/Mylan.

Don't think Cabotegravir is off the table yet, or other products with ViiV.

https://www.freepatentsonline.com/y2023/0405095.html
👍️0
stockrafter stockrafter 2 weeks ago
Wonder if the deal could have any effect on the AI deal with Idorsia?

Viatris was formed from a merger of Mylan and Upjohn. Mylan sold the original Epi Pen. They diversified from theie autoinjector business during the merger. Interesting old Mylan will be selling an ATRS autoinjector product after years of fighting the generic ATRS Epi-Pen.

Viatris is making a big bet on Selatogrel, hope it works out for them. It won't be a huge money maker for HALO, but a nice steady income, after an initial large stocking of packaged AI/Drug combo for the introduction. Long-term it will give increased credibility for ATRS AI products. With the close collaboration, maybe Helen could make some deals with Viatris up coming products. Of which their upcoming products can easily be seen in the informative Pipeline charts in Viatris latest presentation.

"Viatris bets $350 million upfront on two late-stage drugs from Idorsia"

https://firstwordpharma.com/story/5831429

Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration

https://newsroom.viatris.com/2024-02-28-Viatris-and-Idorsia-Enter-Into-Significant-Global-Research-and-Development-Collaboration

https://investor.viatris.com/static-files/4ba5a0bf-5ae4-4425-a697-233a95c6c763
👍️ 1
Fred Kadiddlehopper Fred Kadiddlehopper 2 weeks ago
Interestingly, at Barclays, I noticed Helen mentioned they are seeking potential partnerships in the "nucleic acid"" and "RNA" arena. Is this the first time she has mentioned these potential partners?
👍️0
Fred Kadiddlehopper Fred Kadiddlehopper 2 weeks ago
In Barclay's fireside chat Helen mentioned there are 7 wave 4 products in development and the slide set says the same, however we now know that the Cabotegravir (ViiV) is off the table so there are in fact only 6.
👍️0
Fred Kadiddlehopper Fred Kadiddlehopper 2 weeks ago
Latest Slide Set Feb 2024
https://s28.q4cdn.com/284259014/files/doc_presentation/2024/HALO-Corporate-Deck-February-2024-FINAL.pdf
👍️0
Fred Kadiddlehopper Fred Kadiddlehopper 2 weeks ago
New competition looming for HALO's epipen AI franchise.
https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-pivotal-study-anaphylmtm
👍️0
Fred Kadiddlehopper Fred Kadiddlehopper 2 weeks ago
I think you may be correct. My memory of seeing TED indication might have been from the Horizon deal, which seems to have been abandoned in light of Horizon's newer deal with Xeris.
👍️0
Fred Kadiddlehopper Fred Kadiddlehopper 2 weeks ago
I think you may be correct. My memory of seeing TED indication might have been from the Horizon deal, which seems to have been abandoned.
👍️0
biotechinvestor1 biotechinvestor1 2 weeks ago
Also you can do a word search in their most recent 8k and 10k filings. There is no mention of TED with Efgartigimod (Argenx)
👍️0
biotechinvestor1 biotechinvestor1 2 weeks ago
I think you are incorrect. I don’t ever remember, Halozyme having 2 deals with 2 different partners (Horizon and Argenx) for the same indication (Thyroid Eye Disease).

Also there never a phase 1 or phase 2 study of Rhuph20 (or ph20, or hyaulonidase) combined with Efgartigimod (from argenx) in clinicaltrials.gov

There are 151 trials with rhuph20 (including all the old trials whether completed or not)

Go check it out yourself.
👍️0
Howeeme Howeeme 2 weeks ago
Sorry for the confusion. I’m speaking in general terms about injectors. Not specific to this deal. Getting SC delivery to market quicker will make it very tough for competition against Enhanze. That extra year or two makes a huge difference.
👍️0
Fred Kadiddlehopper Fred Kadiddlehopper 2 weeks ago
Howee, also the study is using a pre-filled syringe, not an auto-injector.
👍️0
Fred Kadiddlehopper Fred Kadiddlehopper 2 weeks ago
I don't think this is a new deal but one that was originally a part of the original ARGX deal which contained multiple targets including thyroid eye disease. I'm not certain about this, though. I do remember seeing something on the (HALO web site maybe?) about that target long before biotechinvestor posted yesterday. Unfortunately HALO chose to take down that useful chart on the partner pipeline so I can't be sure. Bottom line for me is that I'm not treating it as a new target but rather a pre-existing one that is just getting off the ground.
👍️0
Howeeme Howeeme 2 weeks ago
Great find!!!! This should save and make Partners a lot of money. Maybe this makes doing business with Halo vs any would be competitor a no brainer. Maybe Helen knows what she’s doing after all.

Also until recently I really never paid much attention to the injector market. She is definitely on to something.

👍️0
Fred Kadiddlehopper Fred Kadiddlehopper 2 weeks ago
Good pickup, thanks for sharing. Efgartigimod should keep HALO afloat for a while unless ARGX fails another trial.
👍️0
biotechinvestor1 biotechinvestor1 2 weeks ago
… we now are far more advanced in this indication than we ever were with Horizon.
👍️0
biotechinvestor1 biotechinvestor1 2 weeks ago
…They went straight to phase 3 for a new indication with Enhaze. This is what Helen was talking about when she said regulator no longer need non-inferiority data and all they need is PK study.

Expect big PR about this.
👍️ 1
biotechinvestor1 biotechinvestor1 2 weeks ago
2 Brand new studies of Efgartigimod PH20 SC in Adults With Thyroid Eye Disease posted on clinical trials gov for the first time today. One is with a pre-filled syringe.

This is a new indication for Enhanze and Argenx that was not previously disclosed by Halozyme.

https://classic.clinicaltrials.gov/ct2/show/NCT06307613?term=Rhuph20&draw=3&rank=107

https://classic.clinicaltrials.gov/ct2/show/NCT06307626?term=Rhuph20&draw=3&rank=106
👍️ 1
Fred Kadiddlehopper Fred Kadiddlehopper 2 weeks ago
IM administration of Enhanz is highly speculative and probably not sufficiently efficacious due to the much smaller volume of hyaluronan in muscle tisse as compared to the skin matrix.
👍️0
biotechinvestor1 biotechinvestor1 2 weeks ago
From Helen’s talk yesterday:

1) The 20-30% ANNUAL growth in EBITA is based on already approved products (wave 1-3).

Wave 4 and anything beyond will be icing on the cake.

2) EBITA profit margin is expected to GROW to over 70% by 2028. profit margin is already impressive but for it to grow is absolutely terrific.

👍️0
biotechinvestor1 biotechinvestor1 2 weeks ago
Is intramuscular route of admin the next large market ready for disruption by Enhanze? It would be great if Helen comments on this article and its potential for Halozyme tomorrow. This is an IM injectable for a psych indication with huge TAM. https://www.biorxiv.org/content/biorxiv/early/2024/03/06/2024.03.03.583160.full.pdf
👍️0
Fred Kadiddlehopper Fred Kadiddlehopper 2 weeks ago
PPS is just doing what it's done for the past year, cycling within a trading range of low $30w to low $40s. Nothing to see here.
👍️0
maumar maumar 2 weeks ago
No, I haven’t listened to the chat yet. I will try to do it tomorrow. The lack of progress in the clinic for several products together with the lack of new deals is very concerning. And yet the stock has been acting a little better. Nothing to get too excited about, of course.
👍️0
Fred Kadiddlehopper Fred Kadiddlehopper 2 weeks ago
As I read it the other formulation is not dependent on an enzyme. This is the 4th or 5th target that was removed from the pipeline with nothing to replace them. Did you listen to the chat today? Not a hopeful thing to point to. She's blaming the lack of deals for the past few years on the federal price controls which have only been in effect for the past 6 months or so. Complete BS IMHO.
👍️0

Your Recent History

Delayed Upgrade Clock